IL1B and pericarditis: This proved to be the case, as these therapies were withdrawn, and rilonacept monotherapy was achieved in a median of 7.9 weeks without pericarditis recurrence.17 Rapid resolution of acute episodes shortly after initiation of rilonacept during the run-in period indicates that the targeted IL-1 blockade was both necessary and sufficient to control disease.